Navigation Links
Pacira Pharmaceuticals Names David M. Stack CEO and President
Date:12/18/2007

Stack served as the President and General Manager of Innovex, Inc. and was responsible for the Americas. Innovex, Inc. is a commercial solutions company offering a full range of marketing, sales and clinical development capabilities to pharmaceutical and biotechnology customers.

Mr. Stack's prior experience also includes serving as the Vice President of Business Development and Marketing for Immunomedics, Inc. (Nasdaq: IMMU), as well as multiple senior business management positions at Roche Labs. Before he entered the commercial pharmaceutical sector, Mr. Stack was a retail and hospital pharmacist for three years after graduating from Albany College of Pharmacy. He also holds a BS in Biology from Siena College. Dave was recognized as the Ernst and Young Entrepreneur of the Year in 2003 (New Jersey Healthcare). He is a Director of Bio-Imaging Technologies, Inc. (Nasdaq: BITI), Medsite, Inc., PepTx, Inc. and QRxPharma Pty Ltd.

About Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. is a wholly owned subsidiary of Pacira Inc., a Delaware corporation, which is controlled and funded by a group of financial investors including HBM BioVentures (Cayman) Ltd., MPM Capital, OrbiMed Advisors, and Sanderling Ventures. This business is based in San Diego, CA, and formulates, develops and manufactures controlled-release injectable products based on two proprietary drug delivery platforms: DepoFoam(R) and Biosphere(R). Revenues are generated from two marketed products: DepoCyt(R) for lymphomatous meningitis and
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... of New England and the Rhode Island House and senate ... multiple sclerosis, AIDS and other chronic // diseases ... these patients. The new bill allows patients to have possession ... marijuana was illegal. But, the Governor Carcieri still oppose the ...
... has a counter which states that heart conditions became worse ... heart disease when they were fed a soy diet. ... mice carried and were severely affected by the soy diet. ... failure. This study was done by University of Colorado at ...
... a pilot study by The New Women's Health Initiative ... fat but rich in carbohydrates results in negligible weight ... between weight alterations in postmenopausal women Vis a Vis ... in this category were advised to reduce the fat ...
... was misled about the dangers of taking cannabis when the ... than a year ago, the British Home Secretary admits today. ... decision taken by his predecessor, David Blunkett, Charles Clarke said ... link between cannabis and mental illness. He made these damning ...
... in the offing for abdominal aortic aneurysm, a blood vessel condition ... ,This condition, a swelling // in the ... bursts, accounts for 1.36% of deaths in men over 65 in ... for men in that age group, Pulse magazine says. ...
... customers to trap doctors who conduct sex determination tests for ... State’s sex ratio is less than 800 females for every ... would be paid up to Rs.5,000 to help nab diagnostic ... Family Welfare Secretary D.S. Guru said field officers of the ...
Cached Medicine News:Health News:UK public misled over downgrading cannabis: Govt 2Health News:Experts urging artery screening in the UK 2
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 25, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... John H. Johnson as Chief Executive Officer, effective January 31, ... Savient,s board of directors. Mr. Johnson brings significant ... a Senior Vice President of Eli Lilly and Company and ...
... recently launched eCS Inpatient EHR V1.2 (eCS), the first ... medium hospitals. eCS,s uniqueness is the tight linkage of ... a single web-based software solution. The solution is offered ... simplified deployment. "eCS is an affordable solution ...
Cached Medicine Technology:Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 2Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 3Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 4eCareSoft Launches Comprehensive EHR for Small & Medium Hospitals 2
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
... For use as a ... detecting IgG antibody to Toxoplasma ... to rubella virus (rubella IgG), ... IgG) and IgG antibody to ...
... VITROS Anti-HCV assay is the third diagnostic,hepatitis ... Drug,Administration capable of being run in a ... with Intellicheck. Now the laboratory staff,can run ... of more than 27 assays, and provide ...
... For use as a quality ... immunoglobulin M (IgM) antibodies to ... IgM), IgM antibodies to hepatitis ... B e antigen (HBeAg) and ...
Medicine Products: